A jury awarded $5.7 billion in damages in the patent case Taction Technology, Inc. v. Apple Inc., one of the largest in U.S. history. Burford Capital, which has a financial stake, could receive about $1.4 billion if the verdict stands. However, the amount is subject to change through post-trial motions and appeals, and the final payout is uncertain. The case remains in litigation with risks of reduced recovery or total loss, and Burford cautions investors about the uncertain outcome and timing.
The jury verdict in the patent case involving Taction Technology and Apple awarded $5.7 billion in damages. For readers following the Financials sector, here is Pluang's market snapshot as of Sep 28, 2026 09:51 WIB: 49 of 85 priced US Financials stocks rose today. Notable movers include Aegon Ltd. at USD 9.07 with a 3.66% increase and Banco Santander SA at USD 14.68 with a 3.38% increase.
Pi Network has started testing Protocol 28 following the successful completion of Protocol 27, with the Mainnet upgrade scheduled for October 16. Node operators must update to Protocol 28 by October 13 to participate in the upgrade. Despite these tec...
First Hydrogen Corp. has successfully built its unmanned ground vehicle (UGV), achieving a key development milestone and securing exclusive worldwide rights to the related patented technology for the patent's remaining life, with a 1% royalty on sale...
Pump.fun (PUMP) token price fell 4.23% within one hour to $0.004957 on September 28, despite being up 12.10% over the past 24 hours. The drop occurred on Binance's PUMP/USDT market, triggering $110,000 in long position liquidations across Binance, By...
Coiled Therapeutics plans to report initial safety and pharmacokinetic data for its new AO-252 cancer drug formulation by the end of 2026 after dosing up to 30 patients. The new lipid-based softgel aims to improve drug absorption and consistency, wit...
Poolbeg Pharma has dosed eight patients in its TOPICAL trial testing POLB 001 to prevent cytokine release syndrome (CRS), a dangerous immune reaction caused by cancer immunotherapy. The trial targets multiple myeloma patients receiving teclistamab, a...
